{"preliminary_commentary":{"by_channel":{"x_thread":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT06040541","nct_id":"NCT06040541","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06040541. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Dose exploration and dose expansion","label":"RMC-9805 monotherapy arm","type":"EXPERIMENTAL"},{"description":"Dose exploration and dose expansion","label":"RMC-9805 plus RMC-6236 combination arm","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-04-30","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)","Pancreatic Ductal Adenocarcinoma (PDAC)","Advanced Solid Tumors"],"enrollment":{"count":604,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"RMC-9805","otherNames":[],"type":"DRUG"},{"name":"RMC-6236","otherNames":[],"type":"DRUG"}],"last_update":"2026-06-03","lead_sponsor":"Revolution Medicines, Inc.","official_title":"Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG 12D-Mutant Solid Tumors","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Adverse events","timeFrame":"Up to 3 years"},{"measure":"Dose Limiting Toxicities","timeFrame":"21 days"}],"references":[{"citation":"Weller C, Burnett GL, Jiang L, Chakraborty S, Zhang D, Vita NA, Dilly J, Kim E, Maldonato B, Seamon K, Eilerts DF, Milin A, Marquez A, Spradlin J, Helland C, Gould A, Ziv TB, Dinh P, Steele SL, Wang Z, Mu Y, Chugh S, Feng H, Hennessey C, Wang J, Roth J, Rees M, Ronan M, Wolpin BM, Hahn WC, Holderfield M, Wang Z, Koltun ES, Singh M, Gill AL, Smith JAM, Aguirre AJ, Jiang J, Knox JE, Wildes D. A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors. Science. 2025 Jul 24;389(6758):eads0239. doi: 10.1126/science.ads0239. Epub 2025 Jul 24.","pmid":"40705880","type":"DERIVED"},{"citation":"Cregg J, Edwards AV, Chang S, Lee BJ, Knox JE, Tomlinson ACA, Marquez A, Liu Y, Freilich R, Aay N, Wang Y, Jiang L, Jiang J, Wang Z, Flagella M, Wildes D, Smith JAM, Singh M, Wang Z, Gill AL, Koltun ES. Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers. J Med Chem. 2025 Mar 27;68(6):6064-6083. doi: 10.1021/acs.jmedchem.4c02314. Epub 2025 Mar 8.","pmid":"40056080","type":"DERIVED"}],"start_date":{"date":"2023-09-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors","url":"https://clinicaltrials.gov/study/NCT06040541"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06040541"}